Per Kogner | Ruth Palmer Labhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/per-kogner/Per KognerHugo Blox Builder (https://hugoblox.com)en-usSat, 01 Jan 2022 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/media/icon_hua1ac8766117554d27209418f2eeeba33_52656_512x512_fill_lanczos_center_3.pngPer Kognerhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/per-kogner/Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastomahttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/entrectinib_alkal2/Sat, 01 Jan 2022 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/entrectinib_alkal2/11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastomahttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/dlg2_neuroblastoma/Tue, 22 Sep 2020 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/dlg2_neuroblastoma/Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGalpha) in neuroblastoma patient samples with chromosome arm 2p rearrangementshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_patient_samples/Wed, 01 Jan 2020 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_patient_samples/Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinibhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_i1171t/Wed, 01 Aug 2018 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_i1171t/